Hiroshi Komazaki

618 total citations · 1 hit paper
9 papers, 386 citations indexed

About

Hiroshi Komazaki is a scholar working on Dermatology, Physiology and Molecular Biology. According to data from OpenAlex, Hiroshi Komazaki has authored 9 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Dermatology, 4 papers in Physiology and 3 papers in Molecular Biology. Recurrent topics in Hiroshi Komazaki's work include Asthma and respiratory diseases (4 papers), Dermatology and Skin Diseases (4 papers) and Allergic Rhinitis and Sensitization (3 papers). Hiroshi Komazaki is often cited by papers focused on Asthma and respiratory diseases (4 papers), Dermatology and Skin Diseases (4 papers) and Allergic Rhinitis and Sensitization (3 papers). Hiroshi Komazaki collaborates with scholars based in Japan. Hiroshi Komazaki's co-authors include Makoto Kawashima, Kenji Kabashima, Shigeru Hishinuma, Masaru Shoji, Hiroyuki Fukui, Daisuke Watanabe, Atsuyuki Igarashi, Yuko Sato, Yusuke Kobayashi and Toshio Katsunuma and has published in prestigious journals such as New England Journal of Medicine, Journal of Neurochemistry and British Journal of Dermatology.

In The Last Decade

Hiroshi Komazaki

9 papers receiving 374 citations

Hit Papers

Trial of Nemolizumab and Topical Agents for Atopic Dermat... 2020 2026 2022 2024 2020 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Komazaki Japan 8 311 229 108 100 72 9 386
Usman Chaudhry United States 5 429 1.4× 307 1.3× 200 1.9× 90 0.9× 118 1.6× 7 504
Talia Canter United States 6 446 1.4× 347 1.5× 187 1.7× 65 0.7× 94 1.3× 8 503
Sadaf Kasraie Germany 8 295 0.9× 148 0.6× 83 0.8× 74 0.7× 110 1.5× 8 382
Howard Chu South Korea 10 209 0.7× 112 0.5× 57 0.5× 21 0.2× 47 0.7× 22 293
R. Foelster‐Holst Germany 8 208 0.7× 151 0.7× 40 0.4× 25 0.3× 17 0.2× 11 258
Peter Norén Sweden 8 190 0.6× 104 0.5× 55 0.5× 33 0.3× 60 0.8× 8 278
Marlene Seegräber Germany 7 199 0.6× 140 0.6× 74 0.7× 55 0.6× 34 0.5× 14 257
S. Balica France 4 246 0.8× 172 0.8× 41 0.4× 24 0.2× 39 0.5× 7 318
L. Motterle Italy 8 100 0.3× 219 1.0× 45 0.4× 36 0.4× 101 1.4× 9 472
Jan Romantowski Poland 8 92 0.3× 104 0.5× 51 0.5× 45 0.5× 138 1.9× 25 266

Countries citing papers authored by Hiroshi Komazaki

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Komazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Komazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Komazaki more than expected).

Fields of papers citing papers by Hiroshi Komazaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Komazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Komazaki. The network helps show where Hiroshi Komazaki may publish in the future.

Co-authorship network of co-authors of Hiroshi Komazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Komazaki. A scholar is included among the top collaborators of Hiroshi Komazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Komazaki. Hiroshi Komazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
2.
3.
Kawashima, Makoto, et al.. (2022). Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Open Forum Infectious Diseases. 9(10). ofac494–ofac494. 12 indexed citations
4.
Kawashima, Makoto, et al.. (2022). A phase 3, randomized, double‐blind, placebo‐controlled study evaluating a single, patient‐initiated dose of amenamevir for recurrent herpes labialis. The Journal of Dermatology. 50(3). 311–318. 10 indexed citations
6.
Kabashima, Kenji, et al.. (2020). Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. New England Journal of Medicine. 383(2). 141–150. 237 indexed citations breakdown →
7.
Hishinuma, Shigeru, et al.. (2017). Ca2+‐dependent down‐regulation of human histamine H1receptors in Chinese hamster ovary cells. Journal of Neurochemistry. 144(1). 68–80. 4 indexed citations
8.
Hishinuma, Shigeru, Hiroshi Komazaki, Hiroyuki Fukui, & Masaru Shoji. (2010). Ubiquitin/proteasome‐dependent down‐regulation following clathrin‐mediated internalization of histamine H1‐receptors in Chinese hamster ovary cells. Journal of Neurochemistry. 113(4). 990–1001. 14 indexed citations
9.
Hishinuma, Shigeru, Yuko Sato, Yusuke Kobayashi, Hiroshi Komazaki, & Masaki Saito. (2008). Intact Cell Binding for In Vitro Prediction of Sedative and Non-sedative Histamine H1–Receptor Antagonists Based on Receptor Internalization. Journal of Pharmacological Sciences. 107(1). 66–79. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026